Is curing patients a sustainable business model?

S

SirGalahad

Joined
1 Apr 2016
Messages
13,606
Reaction score
550
Country
United Kingdom
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.

"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."

To add to this the US has put Canada on its high priority IP watch list on the same level as China because of concerns over border control and pharmaceutical practices because Canada legally produces generic versions of medicines.

https://www.reuters.com/article/us-...anada-on-ip-priority-watch-list-idUSKBN1HY24J

https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html
 
Is this the forum equivalent of 'retweeting’? Perhaps we should all pick out random headlines and post them up? We should have a section called NFI for people to post this random s hit.
 
Canada is to the US what Southern Ireland is to the UK.. It's economic model is a just a tiny bit parasitical on its neighbour. I do believe however there is a floor in the plan. I'm pretty sure the health regulator (NICE) apply value tests when determining what to pay for meds. So a cure will be more highly valued than a treatment. I think those in research also tend not to think about the economics in so much detail, they are often funded partially by charities who are very much after a cure.
 
If a cure for cancer was found tomorrow I bet cancer research uk would sh1t itself.
 
One of my directors used to reckon that, in a hundred years' time, people would say there was no one thing called cancer, but hundreds of separate ones.
 
Motman said:
Is this the forum equivalent of 'retweeting’? Perhaps we should all pick out random headlines and post them up? We should have a section called NFI for people to post this random s hit.
Click to expand...

Lol.
 
I guess it makes sense to make financial forecasts, if success in curing patients could be bad for business that might mean altering the business model to adjust.

There are lots of things where human ckst is calculated in terms of money. Safety on passenger aircraft for example. Financial modelling is done to see if the cost of a new safety feature is more than the cost of paying out for compensation for the deaths of the passengers.
 
Notch7 said:
I guess it makes sense to make financial forecasts, if success in curing patients could be bad for business that might mean altering the business model to adjust.

There are lots of things where human ckst is calculated in terms of money. Safety on passenger aircraft for example. Financial modelling is done to see if the cost of a new safety feature is more than the cost of paying out for compensation for the deaths of the passengers.
Click to expand...

So you think its acceptable? Should we just leave it to businesses to decide whether to cure or manage the problem based on their profitability targets?
 
Kankerot said:
So you think its acceptable? Should we just leave it to businesses to decide whether to cure or manage the problem based on their profitability targets?
Click to expand...

I think that would depend on whether a business is ethically driven with a requirement for acceptable profit to sustain business growth or whether a business just wants to screw as much profit as possible for management salaries and shareholders.

R&D can only happen with reinvestment from profits. I suppose the question is whether profit driven business model also drive innovation and brings products to market that save and / or extend lives.

Im sure some big Pharma Companies are parasites with overcharging practices. Are Bio tech companies the same?
 
Notch7 said:
I think that would depend on whether a business is ethically driven with a requirement for acceptable profit to sustain business growth or whether a business just wants to screw as much profit as possible for management salaries and shareholders.

R&D can only happen with reinvestment from profits. I suppose the question is whether profit driven business model also drive innovation and brings products to market that save and / or extend lives.

Im sure some big Pharma Companies are parasites with overcharging practices. Are Bio tech companies the same?
Click to expand...

It's an area where there needs to be better regulation. Currently the approach is too reactive.
 
They have something like a 99.9% failure rate, they need to get the cost of failing back from somewhere.
 
You must log in or register to reply here.
Back
Top